PRODUCTS

Investors Osiris

Investors

Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary 11/26/18	Osiris Therapeutics, Inc. Appoints Samson Tom, PhD, MBA to Serve as President and Chief Executive Officer COLUMBIA, Md. , Nov. 26, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, is pleased to announce that its Board of Directors appointed Samson Tom , PhD,	View HTML PDF Version
Toggle Summary 11/07/18	Osiris Therapeutics, Inc Reports Third Quarter 2018 Results COLUMBIA, Md. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, today reported its results for the third quarter ending September 30, 2018 .	View HTML PDF Version
Toggle Summary 10/30/18	Osiris Therapeutics, Inc. to Present Advanced Clinical and Scientific Abstracts at Symposium on Advanced Wound Care (SAWC) Fall Meeting, November 2-4, 2018, in Las Vegas, Nevada COLUMBIA, Md. , Oct. 30, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, will present advanced clinical and scientific research at the Symposium on	View HTML PDF Version
Toggle Summary 10/02/18	Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Demonstrating That Lyopreservation Method Developed for Living Tissues is an Alternative to Cryopreservation with the Convenience of Ambient Storage COLUMBIA, Md. , Oct. 02, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that a new peer-reviewed manuscript entitled “Properties of	View HTML PDF Version
Toggle Summary 09/17/18	Osiris Therapeutics, Inc. Announces GrafixPL PRIME™ Launches October 1, 2018 COLUMBIA, Md. , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announces that GrafixPL PRIME™, a human placental membrane that can be stored	View HTML PDF Version
Toggle Summary 08/27/18	Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Comparing the Efficacy of Viable Cryopreserved Placental Membranes to Human Fibroblast-Derived Dermal Substitute in the Treatment of Chronic Diabetic Foot Ulcers (DFUs) in a Multicenter Randomi COLUMBIA, Md. , Aug. 27, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that a new peer-reviewed manuscript entitled “A multicenter,	View HTML PDF Version
Toggle Summary 08/01/18	Osiris Therapeutics, Inc. to Re-list on The Nasdaq Global Market on August 1, 2018 COLUMBIA, Md. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, today announced that The Nasdaq Stock Market LLC has approved its application to	View HTML PDF Version
Toggle Summary 07/11/18	Osiris Announces Enrollment of Patients in a Clinical Trial Evaluating GrafixPL PRIME™ in the Treatment of Chronic Venous Leg Ulcers COLUMBIA, Md. , July 11, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink:OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced the initiation of its “Multicenter, Prospective, Randomized,	View HTML PDF Version
Toggle Summary 06/04/18	Osiris Announces Implementation of Prestige Lyotechnology℠ Preservation Method Allowing Ambient Storage of Living Tissues COLUMBIA, Md. , June 04, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink:OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today the implementation of Prestige Lyotechnology for manufacturing	View HTML PDF Version
Toggle Summary 04/25/18	Osiris Announces New Peer-Reviewed Publication Summarizing Clinical Outcomes of Viable Cryopreserved Placental Membranes for Management of Chronic Diabetic Foot Ulcers in Real World Setting COLUMBIA, Md. , April 25, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink:OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that a new peer-reviewed manuscript entitled “Effectiveness of	View HTML PDF Version

MENU